CONTEXT: Patients with multiple sclerosis (MS) face many challenges. One significant challenge is long-term adherence to disease-modifying therapy (DMT). Four of the 6 currently available DMTs involve self-injection, and all cause adverse events of varying degrees of severity. Although effective, the benefit of DMTs is difficult to determine on an immediate basis. Healthcare providers must play a major role in recognizing nonadherence and identifying strategies to promote adherence. EVIDENCE ACQUISITION: We conducted a literature search of the MEDLINE database using the search terms "adherence" and "multiple sclerosis" to gather data from relevant studies investigating adherence among patients with MS. EVIDENCE SYNTHESIS: Barriers to maintaining treatment adherence in patients with MS include forgetting the medication, injection anxiety, perceived lack of efficacy, coping with adverse events, and issues with complacency and treatment fatigue. An open and honest healthcare provider-patient relationship is a core element in maintaining motivation and adherence in patients with MS. In addition, continuous education and consistent reinforcement of the value of treatment are essential strategies in the maintenance of treatment adherence. Other strategies to promote adherence include management of treatment expectations and minimization of adverse events. CONCLUSIONS: The chronic nature of MS makes treatment adherence challenging in patients with long-standing disease. Patients and healthcare providers need to work together to establish open lines of communication and a trust-based therapeutic relationship to ensure that patients have the knowledge and skills they need to adhere to long-term MS therapy.
CONTEXT: Patients with multiple sclerosis (MS) face many challenges. One significant challenge is long-term adherence to disease-modifying therapy (DMT). Four of the 6 currently available DMTs involve self-injection, and all cause adverse events of varying degrees of severity. Although effective, the benefit of DMTs is difficult to determine on an immediate basis. Healthcare providers must play a major role in recognizing nonadherence and identifying strategies to promote adherence. EVIDENCE ACQUISITION: We conducted a literature search of the MEDLINE database using the search terms "adherence" and "multiple sclerosis" to gather data from relevant studies investigating adherence among patients with MS. EVIDENCE SYNTHESIS: Barriers to maintaining treatment adherence in patients with MS include forgetting the medication, injection anxiety, perceived lack of efficacy, coping with adverse events, and issues with complacency and treatment fatigue. An open and honest healthcare provider-patient relationship is a core element in maintaining motivation and adherence in patients with MS. In addition, continuous education and consistent reinforcement of the value of treatment are essential strategies in the maintenance of treatment adherence. Other strategies to promote adherence include management of treatment expectations and minimization of adverse events. CONCLUSIONS: The chronic nature of MS makes treatment adherence challenging in patients with long-standing disease. Patients and healthcare providers need to work together to establish open lines of communication and a trust-based therapeutic relationship to ensure that patients have the knowledge and skills they need to adhere to long-term MS therapy.
Authors: Michael D Murray; James Young; Shawn Hoke; Wanzhu Tu; Michael Weiner; Daniel Morrow; Kevin T Stroupe; Jingwei Wu; Daniel Clark; Faye Smith; Irmina Gradus-Pizlo; Morris Weinberger; D Craig Brater Journal: Ann Intern Med Date: 2007-05-15 Impact factor: 25.391
Authors: June Halper; Diego Centonze; Scott D Newsome; DeRen Huang; Christopher Robertson; Xiaojun You; Guido Sabatella; Vladimir Evilevitch; Leslie Leahy Journal: Int J MS Care Date: 2016 Jul-Aug
Authors: Bernard Uitdehaag; Cris Constantinescu; Peter Cornelisse; Douglas Jeffery; Ludwig Kappos; David Li; Magnhild Sandberg-Wollheim; Anthony Traboulsee; Elisabetta Verdun; Victor Rivera Journal: Ther Adv Neurol Disord Date: 2011-01 Impact factor: 6.570
Authors: María Belén Marzal-Alfaro; María Luisa Martín Barbero; JoseM García Domínguez; Fernando Romero-Delgado; María Luisa Martínez Ginés; Ana Herranz; María Sanjurjo-Sáez Journal: Eur J Hosp Pharm Date: 2017-01-13